{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T16:33:04Z","timestamp":1794501184964,"version":"4.9.1"},"reference-count":17,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,10]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>In surgical settings, managing von Willebrand disease (VWD) often requires von Willebrand factor (VWF) concentrate administration, and close monitoring of factor VIII (FVIII) and VWF to balance bleeding control with the risk of excessive factor elevation. This management is further complicated by VWD-related variability and the pharmacokinetic (PK) impact of VWF products, containing or not exogenous FVIII. We hypothesized that building a PK model based on high-purity VWF concentrates may clarify the VWF-FVIII relationship by eliminating exogenous FVIII interference. Our aim was to characterize the PK\/pharmacodynamic (PD) relationship and variability of a high-purity VWF concentrate in patients with VWD undergoing surgery. A retrospective analysis was conducted on patients treated perioperatively with a high-purity plasma-derived VWF concentrate (Wilfactin, Laboratoire Fran\u00e7ais du Fractionnement et des Biotechnologies, France), nearly devoid of FVIII, from January 2016 to December 2018. Data were analyzed using a population PK\/PD modeling approach. VWF antigen (VWF:Ag) was prioritized as it better reflects VWF-FVIII binding capacity rather than VWF activity, which measures platelet interaction. Covariates influencing VWF:Ag and FVIII:C PK\/PD were analyzed. Seventy-four patients undergoing 99 surgeries were included. The model revealed substantial variability in VWF:Ag and FVIII:C volume of distribution, clearance, and baseline levels. Covariates such as age, bodyweight, VWD type, blood group, and VWF propeptide significantly affected PK\/PD parameters. Interindividual variability in PK parameters (eg, clearance, volume), ranged from 25.3% to 73.8%. High interindividual PK\/PD variability was observed with high-purity VWF concentrate. This highlights the need to develop a robust dose-adjustment model to optimize factor concentrate utilization, avoid unnecessary waste, and reduce the frequency of laboratory monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017898","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T19:57:47Z","timestamp":1761076667000},"page":"903-914","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Modeling response to high-purity von Willebrand factor: toward tailored dosing during surgery in von Willebrand disease"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9438-6140","authenticated-orcid":false,"given":"M\u00e9lanie Y.","family":"Daniel","sequence":"first","affiliation":[{"name":"1Universit\u00e9 de Lille, INSERM, Department of Hemostasis and Transfusion, Centre Hospitalier Universitaire de Lille, Institut Pasteur de Lille, Unit 1011-European Genomic Institute for Diabetes, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1182-4131","authenticated-orcid":false,"given":"Antoine","family":"Rauch","sequence":"additional","affiliation":[{"name":"1Universit\u00e9 de Lille, INSERM, Department of Hemostasis and Transfusion, Centre Hospitalier Universitaire de Lille, Institut Pasteur de Lille, Unit 1011-European Genomic Institute for Diabetes, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Paris","sequence":"additional","affiliation":[{"name":"2Department of Hemostasis and Transfusion, Centre Hospitalier Universitaire de Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Jeanpierre","sequence":"additional","affiliation":[{"name":"1Universit\u00e9 de Lille, INSERM, Department of Hemostasis and Transfusion, Centre Hospitalier Universitaire de Lille, Institut Pasteur de Lille, Unit 1011-European Genomic Institute for Diabetes, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Goudemand","sequence":"additional","affiliation":[{"name":"2Department of Hemostasis and Transfusion, Centre Hospitalier Universitaire de Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Marichez","sequence":"additional","affiliation":[{"name":"2Department of Hemostasis and Transfusion, Centre Hospitalier Universitaire de Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Pradines","sequence":"additional","affiliation":[{"name":"2Department of Hemostasis and Transfusion, Centre Hospitalier Universitaire de Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Zawadzki","sequence":"additional","affiliation":[{"name":"2Department of Hemostasis and Transfusion, Centre Hospitalier Universitaire de Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabelle","family":"Dupont","sequence":"additional","affiliation":[{"name":"1Universit\u00e9 de Lille, INSERM, Department of Hemostasis and Transfusion, Centre Hospitalier Universitaire de Lille, Institut Pasteur de Lille, Unit 1011-European Genomic Institute for Diabetes, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5152-9156","authenticated-orcid":false,"given":"C\u00e9cile V.","family":"Denis","sequence":"additional","affiliation":[{"name":"3H\u00e9mostase, Inflammation, Thrombose, Unit\u00e9 Mixte de Recherche_S1176, INSERM, Universit\u00e9 Paris-Saclay, Le Kremlin-Bic\u00eatre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7937-3429","authenticated-orcid":false,"given":"Peter J.","family":"Lenting","sequence":"additional","affiliation":[{"name":"3H\u00e9mostase, Inflammation, Thrombose, Unit\u00e9 Mixte de Recherche_S1176, INSERM, Universit\u00e9 Paris-Saclay, Le Kremlin-Bic\u00eatre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5953-163X","authenticated-orcid":false,"given":"Sophie","family":"Susen","sequence":"additional","affiliation":[{"name":"1Universit\u00e9 de Lille, INSERM, Department of Hemostasis and Transfusion, Centre Hospitalier Universitaire de Lille, Institut Pasteur de Lille, Unit 1011-European Genomic Institute for Diabetes, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7134-0713","authenticated-orcid":false,"given":"Xavier","family":"Delavenne","sequence":"additional","affiliation":[{"name":"4Universit\u00e9 Jean Monnet Saint-\u00c9tienne, Centre Hospitalier Universitaire de Saint-\u00c9tienne, Laboratoire de Pharmacologie et Toxicologie, INSERM, Saint-Etienne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"issue":"1","key":"2026021015530929100_bib1","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1182\/bloodadvances.2020003265","article-title":"ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease","volume":"5","author":"James","year":"2021","journal-title":"Blood Adv"},{"issue":"16","key":"2026021015530929100_bib2","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1182\/blood-2016-04-713289","article-title":"Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A","volume":"128","author":"Pipe","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2026021015530929100_bib3","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/ejh.12809","article-title":"Von Willebrand disease \u2013 the \u2018Dos\u2019 and \u2018Don\u2019ts\u2019 in surgery","volume":"98","author":"Miesbach","year":"2017","journal-title":"Eur J Haematol"},{"issue":"1","key":"2026021015530929100_bib4","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/bloodadvances.2020003264","article-title":"ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease","volume":"5","author":"Connell","year":"2021","journal-title":"Blood Adv"},{"issue":"5","key":"2026021015530929100_bib5","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/j.1365-2516.2011.02583.x","article-title":"Presurgical pharmacokinetic analysis of a von Willebrand factor\/factor VIII (VWF\/FVIII) concentrate in patients with von Willebrand\u2019s disease (VWD) has limited value in dosing for surgery","volume":"17","author":"Di Paola","year":"2011","journal-title":"Haemophilia"},{"issue":"5","key":"2026021015530929100_bib6","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/ejh.12514","article-title":"Interaction between VWF and FVIII in treating VWD","volume":"95","author":"Miesbach","year":"2015","journal-title":"Eur J Haematol"},{"issue":"5","key":"2026021015530929100_bib7","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1182\/bloodadvances.2020003891","article-title":"Population pharmacokinetics of the von Willebrand factor-factor VIII interaction in patients with von Willebrand disease","volume":"5","author":"Bukkems","year":"2021","journal-title":"Blood Adv"},{"issue":"2","key":"2026021015530929100_bib8","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/jth.14652","article-title":"One piece of the puzzle: population pharmacokinetics of FVIII during perioperative Haemate P\/Humate P treatment in von Willebrand disease patients","volume":"18","author":"de Jager","year":"2020","journal-title":"J Thromb Haemost"},{"key":"2026021015530929100_bib9","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2147\/JBM.S395845","article-title":"Pharmacokinetic-pharmacodynamic comparison of recombinant and plasma-derived von Willebrand factor in patients with von Willebrand disease type 3","volume":"14","author":"Bauer","year":"2023","journal-title":"J Blood Med"},{"issue":"4","key":"2026021015530929100_bib10","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1177\/1076029617715117","article-title":"Major and minor classifications for surgery in people with hemophilia: a literature review","volume":"24","author":"Solimeno","year":"2018","journal-title":"Clin Appl Thromb Hemost"},{"issue":"4","key":"2026021015530929100_bib11","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/BF01061691","article-title":"Comparison of four basic models of indirect pharmacodynamic responses","volume":"21","author":"Dayneka","year":"1993","journal-title":"J Pharmacokinet Biopharm"},{"key":"2026021015530929100_bib12","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1051\/ps:2004007","article-title":"Coupling a stochastic approximation version of EM with an MCMC procedure","volume":"8","author":"Kuhn","year":"2004","journal-title":"ESAIM: PS"},{"key":"2026021015530929100_bib13","unstructured":"The R Core Team\n          . R: A Language and Environment for Statistical Computing. Version 4.5.1. Accessed 25 April 2025. https:\/\/cran.r-project.org\/doc\/manuals\/r-release\/fullrefman.pdf."},{"issue":"7","key":"2026021015530929100_bib14","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/jth.12586","article-title":"von Willebrand disease and aging: an evolving phenotype","volume":"12","author":"Sanders","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"7","key":"2026021015530929100_bib15","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-11-122945","article-title":"A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor","volume":"111","author":"Gallinaro","year":"2008","journal-title":"Blood"},{"issue":"6","key":"2026021015530929100_bib16","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1182\/blood.V69.6.1691.1691","article-title":"The effect of ABO blood group on the diagnosis of von Willebrand disease","volume":"69","author":"Gill","year":"1987","journal-title":"Blood"},{"issue":"4","key":"2026021015530929100_bib17","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/jth.12867","article-title":"No evidence for a direct effect of von Willebrand factor\u2019s ABH blood group antigens on von Willebrand factor clearance","volume":"13","author":"Groeneveld","year":"2015","journal-title":"J Thromb Haemost"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/3\/903\/2503538\/blooda_adv-2025-017898-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/3\/903\/2503538\/blooda_adv-2025-017898-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T20:53:13Z","timestamp":1770756793000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/3\/903\/547857\/Modeling-response-to-high-purity-von-Willebrand"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017898","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2,10]]},"published":{"date-parts":[[2026,2,10]]}}}